Huahai has another class of new drugs to attack into the 10 billion eye market.

Pharmaceutical Network October 9th, September 28th, Huahai Pharmaceuticals announced that huabo Bio,a subsidiary of the recombinant human vascular endodertic growth factor subject - antibody fusion protein eye injection (HB002.1M) project 3 new adaptations, approved clinically by the State Drug Administration.
To date, HB002.1M has been approved for clinical use of 4 adaptive disorders (wet age-related macular degeneration, retinal branch vein blockage secondary macular edema, retinal central venous blockage secondary macular edema, and diabetic macular edema).
age-related macular degeneration trial of HB002.1M has progressed to Phase II clinical.
HB002.1M is a recombinant fusion protein with vascular enditer growth factor (VEGF) as its target, and has been listed at home and abroad with the same target, the same therapeutic field drugs including leizhu monoantigen, Abersip and Compaxip. According to
meters of intranet data, in 2019, China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal ophthalmology sales exceeded 11 billion yuan, an increase of 16.62 percent year-on-year.
China's public medical institutions terminal ophthalmology drug sales (units: 100 million yuan) Source: Minet China's public medical institutions terminal competition pattern since this year, Huahai Pharmaceuticals has 3 new drugs approved clinical, respectively, recombinant human vascular endotkin growth factor subject - antibody fusion protein eye injection, HOT-1030 injection, HB0017 injection.
2020 to date, Huahai Pharmaceutical Co., Ltd. has been approved clinically approved as a class 1 new drug HOT-1030 injection is a CD137 (4-1BB) as the target of monoclonal antibodies, intended for the treatment of advanced malignant solid tumors.
drugs targeted by CD137 (4-1BB) have not been marketed so far.
HB0017 injection is a monoclonal antibody with white methicillin-17 (IL-17) as its target, intended for the treatment of psoriasis, psoriasis arthritis and mandatory spina brysitis, IL-17 is an important treatment target for this type of disease.
the same target (IL-17/IL-17 subject) drugs already on the market at home and abroad include Cosentyx (Skuchiyu monoanti) and Taltz (Ichizhu monoanti).
September 29, Huahai Pharmaceuticals released its first three-quarter earnings forecast, forecasting a net profit of 820 million yuan - 870 million yuan in the First Nine months of 2020, up about 60% to 70% YoY.
increase in domestic product performance was mainly due to the impact of a significant increase in sales of domestic preparations and API.
among the three batches carried out in the country, Huahai Pharmaceuticals has a total of 12 varieties selected national volume procurement, collection of winning bid to help the company's products quickly open the market, to promote a substantial increase in domestic preparation sales.
.